Research programme: inflammation therapy - Amgen/Schering-Plough

Drug Profile

Research programme: inflammation therapy - Amgen/Schering-Plough

Latest Information Update: 08 Sep 2008

Price : $50

At a glance

  • Originator Amgen; Schering-Plough
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 08 Sep 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough
  • 06 Aug 2003 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top